Physician profile
Peter B Soh
NPI 1508398942
$60,482.17
in general payments reported to CMS, 2019-2025
22 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $704 · 2021: $433 · 2022: $681 · 2023: $626 · 2024: $36K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $13K · Food and Beverage: $3,054 · Travel and Lodging: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,391.25 |
| Consulting Fee | $12,575.00 |
| Food and Beverage | $3,053.92 |
| Travel and Lodging | $2,118.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31,370.80 | 2023-2025 | |
| Abbvie INC. | $26,057.92 | 2021-2025 | Qulipta |
| Lundbeck LLC | $1,388.45 | 2020-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $374.66 | 2019-2021 | |
| Acorda Therapeutics, INC | $254.35 | 2019-2021 | |
| Genentech USA, INC. | $207.56 | 2019-2020 | |
| Lilly USA, LLC | $179.52 | 2020-2022 | |
| Eisai INC. | $103.95 | 2020-2021 | |
| Emd Serono, INC. | $98.95 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $90.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $87.02 | 2020 | |
| Supernus Pharmaceuticals, INC. | $56.11 | 2020-2021 | |
| Greenwich Biosciences, INC. | $49.57 | 2021 | |
| Horizon Therapeutics Plc | $25.65 | 2021 | |
| Sk Life Science, INC. | $24.51 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $19.38 | 2020 | |
| Allergan, INC. | $19.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.45 | 2021 | |
| Amgen INC. | $16.82 | 2020 | |
| Adamas Pharmaceuticals, INC. | $15.60 | 2020 | |
| Biogen, INC. | $12.42 | 2020 | |
| Biomarin Pharmaceutical INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Soh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.